Vascular-targeting agent explained

A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.^[1]

VTAs can be small-molecule or ligand-based.

Small-molecule VTAs include:

• microtubule destabilizing drugs such as combretastatin A-4 disodium phosphate (CA4P), ZD6126, AVE8062, Oxi 4503
• vadimezan (ASA404)

Clinical trials

Phase II : ZD6126, CA4P, plinabulin (NPI-2358)^{[2] [3] [4]}

Phase III : DMXAA (ASA404).

Notes and References

1. Vascular Targeting Agents as Cancer Therapeutics . 2004 . 10.1158/1078-0432.CCR-0642-03 . Thorpe . Philip E. . Clinical Cancer Research . 10 . 2 . 415–427 . 14760060 . 1739027 .
2. Web site: NPI-2358 . clinicaltrials.gov.
3. Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas . Monica M. Mita. 10.1158/1078-0432.CCR-10-1096 . Clin Cancer Res . 2010 . 16 . 23 . 5892–5899 . 21138873. etal. free .
4. Clinical Trials Update . 2009 . Staff . Genetic Engineering & Biotechnology News . 58 . 29 . 8.